Innovating.works Conecta tu I+D

MC4DD: Macrocycles for Drug Discovery Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe. New d...
2024-07-10 - 2028-10-31 | Financiado

GUIDE.MRD: GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD ABBVIE DEUTSCHLAND GMBH CO KG participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved o...
2023-05-17 - 2028-04-30 | Financiado

IMPRiND: Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases Sofia ref. 116060 ABBVIE DEUTSCHLAND GMBH CO KG participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic direct...
2017-04-07 - 2022-02-28 | Financiado

IB4SD-TRISTAN: Imaging Biomarkers IBs for Safer Drugs Validation of Translational Imaging Methods in Drug Safety... ABBVIE DEUTSCHLAND GMBH CO KG participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage 1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized exp...
2017-03-10 - 2024-12-31 | Financiado

TransQST: Translational quantitative systems toxicology to improve the understanding of the safety of medicine... ABBVIE DEUTSCHLAND GMBH CO KG participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new me...
2016-12-22 - 2022-08-31 | Financiado

PHAGO: Inflammation and AD modulating microglia function focussing on TREM2 and CD33 Sofia ref. 115976 ABBVIE DEUTSCHLAND GMBH CO KG participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage Alzheimer’s disease (AD) is an age-related chronic neurodegenerative disease with four main pathological changes in the brain: amyloid plaqu...
2016-12-16 - 2022-04-30 | Financiado

ADAPTED: Alzheimers Disease Apolipoprotein Pathology for Treatment Elucidation and Development Sofia ref.... ABBVIE DEUTSCHLAND GMBH CO KG participó en un H2020: H2020-JTI-IMI2-2015-05-two-stage APOEɛ4 has long been known as a risk factor of LOAD, yet the biological mechanisms through which it acts remain largely unknown and affect b...
2016-11-09 - 2020-09-30 | Financiado

COMPACT: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP6: Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from...
2012-11-01 - 2017-10-31 | Financiado

ORBITO: Oral biopharmaceutics tools ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP6: The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug de...
2012-10-01 - 2018-09-30 | Financiado

STEMBANCC: Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP6: StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug disc...
2012-10-01 - 2018-03-31 | Financiado

MIP-DILI: Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP6: The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will addres...
2012-02-01 - 2017-03-31 | Financiado

EUROPAIN: Understanding chronic pain and improving its treatment ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP6: We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational resear...
2009-10-01 - 2015-09-30 | Financiado

NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP6: Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are...
2009-09-01 - 2015-02-28 | Financiado

NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP7: Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are...
Financiado

EUROPAIN: Understanding chronic pain and improving its treatment ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP7: We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational resear...
Financiado

MIP-DILI: Mechanism Based Integrated Systems for the Prediction of Drug Induced Liver Injury ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP7: The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will addres...
Financiado

COMPACT: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP7: Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from...
Financiado

STEMBANCC: Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology StemBANCC ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP7: StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug disc...
Financiado

ORBITO: Oral biopharmaceutics tools ABBVIE DEUTSCHLAND GMBH CO KG participó en un FP7: The OrBiTo project will deliver novel methods and a framework for rational application of predictive biopharmaceutics tools for oral drug de...
Financiado